BAY 2599023 (DTX 201)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BAY 2599023 (DTX 201), covering 2026-04-17 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle" [Phase 1, Phase 2]